1018-P: Ultra-Rapid Lispro (URLi) Showed Greater Reduction in Postprandial Glucose (PPG) vs. Humalog in Children, Adolescents, and Adult Patients with Type 1 Diabetes (T1D)
URLi is a novel insulin lispro formulation that was developed to more closely match physiological insulin secretion. This 2-site, randomized, 2-period crossover, double-blind study evaluated the pharmacokinetics and glucodynamics during a liquid test meal, after a single 0.2 U/kg SC dose of URLi or...
Gespeichert in:
| Veröffentlicht in: | Diabetes (New York, N.Y.) N.Y.), 2020-06, Vol.69 (Supplement_1) |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Supplement_1 |
| container_start_page | |
| container_title | Diabetes (New York, N.Y.) |
| container_volume | 69 |
| creator | ARONSON, RONNIE LINNEBJERG, HELLE LEOHR, JENNIFER LABELL, ELIZABETH S. COUTANT, DAVID E. ZHANG, QIANYI DANNE, THOMAS POLLOM, ROBYN K. |
| description | URLi is a novel insulin lispro formulation that was developed to more closely match physiological insulin secretion. This 2-site, randomized, 2-period crossover, double-blind study evaluated the pharmacokinetics and glucodynamics during a liquid test meal, after a single 0.2 U/kg SC dose of URLi or Humalog in 13 children, 14 adolescents, 15 adults with T1D. Onset of insulin appearance was faster with URLi vs. Humalog in children (1.1 vs. 6.5 min; p=0.0002), adolescents (1.9 vs. 6.4 min; p=0.001), and adults (0.9 vs. 4.8 min; p=0.004). Early exposure (AUC0-15min) was greater with URLi vs. Humalog: 7-fold (p |
| doi_str_mv | 10.2337/db20-1018-P |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2419454363</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2419454363</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1063-5d733b96b438d6f2f52b13a2d75e003b5a133042266f219def60637159593ad93</originalsourceid><addsrcrecordid>eNotkd1q4zAQhcXShabZveoLDOxNQuNW0vin2ruStslCoCZNoHdGtuSNimO5ktzSd9qHrE2WuRg4880MnEPIJaPXHDG7USWnEaPsNsq_kQkTKCLk2csZmVDKeMQykZ2TC-9fKaXpUBPy70T_hn0TnIy2sjMKNsZ3zsJsv92YOTwf7IdWsHJaBu1gq1VfBWNbMC3k1ofOyVYZ2cCq6SvrNczyfDWHd38N6_4oG_t3JJcH0yin2wXcKdtoX-k2-AUMq4PQNwFyGcyowYcJB9h9dhoY3BtZ6qA9zHbsfv6DfK9l4_XP_31K9o8Pu-U62jyt_izvNlHFaIpRojLEUqRljLcqrXmd8JKh5CpLNKVYJpIh0pjzdBgyoXQ9eIEZS0QiUCqBU_LrdHdw4a3XPhSvtnft8LLgMRNxEmOKA3V1oipnvXe6LjpnjtJ9FowWYxzFGEcxGlzk-AVNSXni</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2419454363</pqid></control><display><type>article</type><title>1018-P: Ultra-Rapid Lispro (URLi) Showed Greater Reduction in Postprandial Glucose (PPG) vs. Humalog in Children, Adolescents, and Adult Patients with Type 1 Diabetes (T1D)</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>ARONSON, RONNIE ; LINNEBJERG, HELLE ; LEOHR, JENNIFER ; LABELL, ELIZABETH S. ; COUTANT, DAVID E. ; ZHANG, QIANYI ; DANNE, THOMAS ; POLLOM, ROBYN K.</creator><creatorcontrib>ARONSON, RONNIE ; LINNEBJERG, HELLE ; LEOHR, JENNIFER ; LABELL, ELIZABETH S. ; COUTANT, DAVID E. ; ZHANG, QIANYI ; DANNE, THOMAS ; POLLOM, ROBYN K.</creatorcontrib><description>URLi is a novel insulin lispro formulation that was developed to more closely match physiological insulin secretion. This 2-site, randomized, 2-period crossover, double-blind study evaluated the pharmacokinetics and glucodynamics during a liquid test meal, after a single 0.2 U/kg SC dose of URLi or Humalog in 13 children, 14 adolescents, 15 adults with T1D. Onset of insulin appearance was faster with URLi vs. Humalog in children (1.1 vs. 6.5 min; p=0.0002), adolescents (1.9 vs. 6.4 min; p=0.001), and adults (0.9 vs. 4.8 min; p=0.004). Early exposure (AUC0-15min) was greater with URLi vs. Humalog: 7-fold (p<0.0001) in children, 4 fold (p=0.0003) in adolescents, 5-fold (p<0.0001) in adults; late exposure (AUC3-7h) was reduced by 58% (p<0.0001) in children, 40% (p=0.013) in adolescents, 37% (p=0.021) in adults. Total exposure was similar in URLi and Humalog. At 1h, URLi reduced PPG by 42 mg/dL (p=0.008) in children, 19 mg/dL (p=0.195) in adolescents, 34 mg/dL (p=0.018) in adults, vs. Humalog. At 2h, URLi reduced the PPG by 32 mg/dL (p=0.11) in children, 39 mg/dL (p=0.051) in adolescents and was not statistically different in adults, vs. Humalog. URLi was well tolerated in all age groups.
In summary, URLi accelerated insulin lispro absorption, reduced late exposure and early PPG following a test meal vs. Humalog in children, adolescents, and adults with T1D.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db20-1018-P</identifier><language>eng</language><publisher>New York: American Diabetes Association</publisher><subject>Adolescents ; Children ; Diabetes ; Diabetes mellitus (insulin dependent) ; Insulin ; Insulin secretion ; Pediatrics ; Pharmacokinetics ; Teenagers</subject><ispartof>Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)</ispartof><rights>Copyright American Diabetes Association Jun 1, 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1063-5d733b96b438d6f2f52b13a2d75e003b5a133042266f219def60637159593ad93</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids></links><search><creatorcontrib>ARONSON, RONNIE</creatorcontrib><creatorcontrib>LINNEBJERG, HELLE</creatorcontrib><creatorcontrib>LEOHR, JENNIFER</creatorcontrib><creatorcontrib>LABELL, ELIZABETH S.</creatorcontrib><creatorcontrib>COUTANT, DAVID E.</creatorcontrib><creatorcontrib>ZHANG, QIANYI</creatorcontrib><creatorcontrib>DANNE, THOMAS</creatorcontrib><creatorcontrib>POLLOM, ROBYN K.</creatorcontrib><title>1018-P: Ultra-Rapid Lispro (URLi) Showed Greater Reduction in Postprandial Glucose (PPG) vs. Humalog in Children, Adolescents, and Adult Patients with Type 1 Diabetes (T1D)</title><title>Diabetes (New York, N.Y.)</title><description>URLi is a novel insulin lispro formulation that was developed to more closely match physiological insulin secretion. This 2-site, randomized, 2-period crossover, double-blind study evaluated the pharmacokinetics and glucodynamics during a liquid test meal, after a single 0.2 U/kg SC dose of URLi or Humalog in 13 children, 14 adolescents, 15 adults with T1D. Onset of insulin appearance was faster with URLi vs. Humalog in children (1.1 vs. 6.5 min; p=0.0002), adolescents (1.9 vs. 6.4 min; p=0.001), and adults (0.9 vs. 4.8 min; p=0.004). Early exposure (AUC0-15min) was greater with URLi vs. Humalog: 7-fold (p<0.0001) in children, 4 fold (p=0.0003) in adolescents, 5-fold (p<0.0001) in adults; late exposure (AUC3-7h) was reduced by 58% (p<0.0001) in children, 40% (p=0.013) in adolescents, 37% (p=0.021) in adults. Total exposure was similar in URLi and Humalog. At 1h, URLi reduced PPG by 42 mg/dL (p=0.008) in children, 19 mg/dL (p=0.195) in adolescents, 34 mg/dL (p=0.018) in adults, vs. Humalog. At 2h, URLi reduced the PPG by 32 mg/dL (p=0.11) in children, 39 mg/dL (p=0.051) in adolescents and was not statistically different in adults, vs. Humalog. URLi was well tolerated in all age groups.
In summary, URLi accelerated insulin lispro absorption, reduced late exposure and early PPG following a test meal vs. Humalog in children, adolescents, and adults with T1D.</description><subject>Adolescents</subject><subject>Children</subject><subject>Diabetes</subject><subject>Diabetes mellitus (insulin dependent)</subject><subject>Insulin</subject><subject>Insulin secretion</subject><subject>Pediatrics</subject><subject>Pharmacokinetics</subject><subject>Teenagers</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNotkd1q4zAQhcXShabZveoLDOxNQuNW0vin2ruStslCoCZNoHdGtuSNimO5ktzSd9qHrE2WuRg4880MnEPIJaPXHDG7USWnEaPsNsq_kQkTKCLk2csZmVDKeMQykZ2TC-9fKaXpUBPy70T_hn0TnIy2sjMKNsZ3zsJsv92YOTwf7IdWsHJaBu1gq1VfBWNbMC3k1ofOyVYZ2cCq6SvrNczyfDWHd38N6_4oG_t3JJcH0yin2wXcKdtoX-k2-AUMq4PQNwFyGcyowYcJB9h9dhoY3BtZ6qA9zHbsfv6DfK9l4_XP_31K9o8Pu-U62jyt_izvNlHFaIpRojLEUqRljLcqrXmd8JKh5CpLNKVYJpIh0pjzdBgyoXQ9eIEZS0QiUCqBU_LrdHdw4a3XPhSvtnft8LLgMRNxEmOKA3V1oipnvXe6LjpnjtJ9FowWYxzFGEcxGlzk-AVNSXni</recordid><startdate>20200601</startdate><enddate>20200601</enddate><creator>ARONSON, RONNIE</creator><creator>LINNEBJERG, HELLE</creator><creator>LEOHR, JENNIFER</creator><creator>LABELL, ELIZABETH S.</creator><creator>COUTANT, DAVID E.</creator><creator>ZHANG, QIANYI</creator><creator>DANNE, THOMAS</creator><creator>POLLOM, ROBYN K.</creator><general>American Diabetes Association</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20200601</creationdate><title>1018-P: Ultra-Rapid Lispro (URLi) Showed Greater Reduction in Postprandial Glucose (PPG) vs. Humalog in Children, Adolescents, and Adult Patients with Type 1 Diabetes (T1D)</title><author>ARONSON, RONNIE ; LINNEBJERG, HELLE ; LEOHR, JENNIFER ; LABELL, ELIZABETH S. ; COUTANT, DAVID E. ; ZHANG, QIANYI ; DANNE, THOMAS ; POLLOM, ROBYN K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1063-5d733b96b438d6f2f52b13a2d75e003b5a133042266f219def60637159593ad93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescents</topic><topic>Children</topic><topic>Diabetes</topic><topic>Diabetes mellitus (insulin dependent)</topic><topic>Insulin</topic><topic>Insulin secretion</topic><topic>Pediatrics</topic><topic>Pharmacokinetics</topic><topic>Teenagers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ARONSON, RONNIE</creatorcontrib><creatorcontrib>LINNEBJERG, HELLE</creatorcontrib><creatorcontrib>LEOHR, JENNIFER</creatorcontrib><creatorcontrib>LABELL, ELIZABETH S.</creatorcontrib><creatorcontrib>COUTANT, DAVID E.</creatorcontrib><creatorcontrib>ZHANG, QIANYI</creatorcontrib><creatorcontrib>DANNE, THOMAS</creatorcontrib><creatorcontrib>POLLOM, ROBYN K.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ARONSON, RONNIE</au><au>LINNEBJERG, HELLE</au><au>LEOHR, JENNIFER</au><au>LABELL, ELIZABETH S.</au><au>COUTANT, DAVID E.</au><au>ZHANG, QIANYI</au><au>DANNE, THOMAS</au><au>POLLOM, ROBYN K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>1018-P: Ultra-Rapid Lispro (URLi) Showed Greater Reduction in Postprandial Glucose (PPG) vs. Humalog in Children, Adolescents, and Adult Patients with Type 1 Diabetes (T1D)</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2020-06-01</date><risdate>2020</risdate><volume>69</volume><issue>Supplement_1</issue><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>URLi is a novel insulin lispro formulation that was developed to more closely match physiological insulin secretion. This 2-site, randomized, 2-period crossover, double-blind study evaluated the pharmacokinetics and glucodynamics during a liquid test meal, after a single 0.2 U/kg SC dose of URLi or Humalog in 13 children, 14 adolescents, 15 adults with T1D. Onset of insulin appearance was faster with URLi vs. Humalog in children (1.1 vs. 6.5 min; p=0.0002), adolescents (1.9 vs. 6.4 min; p=0.001), and adults (0.9 vs. 4.8 min; p=0.004). Early exposure (AUC0-15min) was greater with URLi vs. Humalog: 7-fold (p<0.0001) in children, 4 fold (p=0.0003) in adolescents, 5-fold (p<0.0001) in adults; late exposure (AUC3-7h) was reduced by 58% (p<0.0001) in children, 40% (p=0.013) in adolescents, 37% (p=0.021) in adults. Total exposure was similar in URLi and Humalog. At 1h, URLi reduced PPG by 42 mg/dL (p=0.008) in children, 19 mg/dL (p=0.195) in adolescents, 34 mg/dL (p=0.018) in adults, vs. Humalog. At 2h, URLi reduced the PPG by 32 mg/dL (p=0.11) in children, 39 mg/dL (p=0.051) in adolescents and was not statistically different in adults, vs. Humalog. URLi was well tolerated in all age groups.
In summary, URLi accelerated insulin lispro absorption, reduced late exposure and early PPG following a test meal vs. Humalog in children, adolescents, and adults with T1D.</abstract><cop>New York</cop><pub>American Diabetes Association</pub><doi>10.2337/db20-1018-P</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-1797 |
| ispartof | Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1) |
| issn | 0012-1797 1939-327X |
| language | eng |
| recordid | cdi_proquest_journals_2419454363 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Adolescents Children Diabetes Diabetes mellitus (insulin dependent) Insulin Insulin secretion Pediatrics Pharmacokinetics Teenagers |
| title | 1018-P: Ultra-Rapid Lispro (URLi) Showed Greater Reduction in Postprandial Glucose (PPG) vs. Humalog in Children, Adolescents, and Adult Patients with Type 1 Diabetes (T1D) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T15%3A04%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=1018-P:%20Ultra-Rapid%20Lispro%20(URLi)%20Showed%20Greater%20Reduction%20in%20Postprandial%20Glucose%20(PPG)%20vs.%20Humalog%20in%20Children,%20Adolescents,%20and%20Adult%20Patients%20with%20Type%201%20Diabetes%20(T1D)&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=ARONSON,%20RONNIE&rft.date=2020-06-01&rft.volume=69&rft.issue=Supplement_1&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db20-1018-P&rft_dat=%3Cproquest_cross%3E2419454363%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2419454363&rft_id=info:pmid/&rfr_iscdi=true |